Hai Nguyen, MD
Internal Medicine · Gretna, LANPI 1235295551
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,365 of the $4,924 with a category attached, or 88.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,071 and has fallen 72.1% since, to $299 in 2025.
Across 280 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$967
- Lilly USA, LLC$923
- Eko Health, Inc.$500
- Novo Nordisk$395
- Pfizer$310
- Boehringer Ingelheim$244
- plus $2K from 22 others
Across 44 payments — averaging $7842.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$341K
- AbbVie$5K
What the payments were for
- Food & beverage$4,36589%
- Gifts$55911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $967 |
| Lilly USA, LLC | 59 | $923 |
| Eko Health, Inc. | 1 | $500 |
| Novo Nordisk | 25 | $395 |
| Pfizer | 28 | $310 |
| Boehringer Ingelheim | 17 | $244 |
| Bayer | 16 | $238 |
| Merck | 13 | $168 |
| AstraZeneca | 10 | $147 |
| VBI Vaccine (delaware) Inc. | 6 | $146 |
| Corcept Therapeutics | 7 | $140 |
| Aerin Medical Inc. | 1 | $101 |
| Amarin Pharma, Inc. | 5 | $95 |
| Abbott | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Mannkind Corporation | 1 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Cipher Pharmaceuticals US LLC | 1 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Boston Scientific | 1 | $17 |
| GSK | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vivaer RF Stylus$101
How this compares
$4,924 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 169 | $179,719 |
| TrulicityDulaglutide | 135 | $175,672 |
| OzempicSemaglutide | 164 | $170,114 |
| JanuviaSitagliptin Phosphate | 54 | $69,229 |
| KerendiaFinerenone | 66 | $68,110 |
| JardianceEmpagliflozin | 49 | $59,491 |
| VascepaIcosapent Ethyl | 29 | $16,558 |
| LinzessLinaclotide | 15 | $11,212 |
| FarxigaDapagliflozin Propanediol | 17 | $10,576 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $9,518 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $8,602 |
| XareltoRivaroxaban | 13 | $7,662 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 234 | $5,279 |
| Azelastine Hcl | 148 | $4,500 |
| Omega-3 Acid Ethyl Esters | 32 | $3,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $923 | $355,391304 claims |
| Novo NordiskOzempic | $395 | $170,114164 claims |
| MerckJanuvia | $168 | $69,22954 claims |
| BayerKerendia | $238 | $68,11066 claims |
| Boehringer IngelheimJardiance | $244 | $59,49149 claims |
| AstraZenecaFarxiga, Symbicort | $147 | $20,09556 claims |
| AbbVieLinzess | $967 | $11,21215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Gretna
- Everett BrownGretna$71K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
- Bryan LebeanLafayette$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.